For Wyeth, More Delays And Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III methylnaltrexone study fails to show benefit over placebo, as Wyeth also pulls Pristiq’s EU vasomotor symptoms application.